Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001415889-25-015487
Filing Date
2025-06-03
Accepted
2025-06-03 21:54:54
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 16092
2 JOINT FILING AGREEMENT ex-99-06042025_010655.htm EX-99.1 2970
  Complete submission text file 0001415889-25-015487.txt   20556
Mailing Address 200 GARRETT STREET SUITE S CHARLOTTESVILLE VA 22902
Business Address
Manning Paul B (Filed by) CIK: 0001494695 (see all company filings)

Type: SCHEDULE 13D/A

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Subject) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91724 | Film No.: 251021799
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)